PL3646854T3 - Kompozycje do transfekcji mrna do komórki i ich zastosowania - Google Patents

Kompozycje do transfekcji mrna do komórki i ich zastosowania

Info

Publication number
PL3646854T3
PL3646854T3 PL18306417.9T PL18306417T PL3646854T3 PL 3646854 T3 PL3646854 T3 PL 3646854T3 PL 18306417 T PL18306417 T PL 18306417T PL 3646854 T3 PL3646854 T3 PL 3646854T3
Authority
PL
Poland
Prior art keywords
compositions
applications
cell
transfecting mrna
transfecting
Prior art date
Application number
PL18306417.9T
Other languages
English (en)
Inventor
Fabrice Stock
Valérie TOUSSAINT MOREAU
Patrick Erbacher
Original Assignee
Polyplus Transfection
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polyplus Transfection filed Critical Polyplus Transfection
Publication of PL3646854T3 publication Critical patent/PL3646854T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90Stable introduction of foreign DNA into chromosome
    • C12N15/902Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
PL18306417.9T 2018-10-30 2018-10-30 Kompozycje do transfekcji mrna do komórki i ich zastosowania PL3646854T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18306417.9A EP3646854B1 (en) 2018-10-30 2018-10-30 Compositions for transfecting mrna into a cell and their applications

Publications (1)

Publication Number Publication Date
PL3646854T3 true PL3646854T3 (pl) 2023-01-02

Family

ID=64572258

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18306417.9T PL3646854T3 (pl) 2018-10-30 2018-10-30 Kompozycje do transfekcji mrna do komórki i ich zastosowania

Country Status (14)

Country Link
US (1) US20210386841A1 (pl)
EP (1) EP3646854B1 (pl)
JP (1) JP2022512983A (pl)
KR (1) KR20210084511A (pl)
CN (1) CN112930172B (pl)
AU (1) AU2019373387A1 (pl)
CA (1) CA3113877A1 (pl)
DK (1) DK3646854T3 (pl)
ES (1) ES2927532T3 (pl)
IL (1) IL282579A (pl)
PL (1) PL3646854T3 (pl)
PT (1) PT3646854T (pl)
SG (1) SG11202103117RA (pl)
WO (1) WO2020089342A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022006534A2 (pt) 2019-10-24 2022-07-05 Novago Therapeutics Ag Anticorpos anti-nogo-a
WO2021245184A1 (en) 2020-06-02 2021-12-09 Neurimmune Ag HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
WO2024003363A1 (en) * 2022-06-30 2024-01-04 Universiteit Gent Cationic amphiphilic compound-based nanoparticle compositions
WO2024008967A1 (en) 2022-07-08 2024-01-11 Polyplus Transfection Lipid nanoparticles comprising an imidazolium-based cationic lipid

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5627159A (en) 1994-10-27 1997-05-06 Life Technologies, Inc. Enhancement of lipid cationic transfections in the presence of serum
FR2732895B1 (fr) * 1995-04-11 1997-05-16 Pasteur Merieux Serums Vacc Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament
ATE383331T1 (de) 1998-11-12 2008-01-15 Invitrogen Corp Transportreagentien
EP1844772A1 (en) 2006-04-06 2007-10-17 Polyplus-Transfection SA Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications
EP2860255A1 (en) * 2013-10-14 2015-04-15 Technische Universität Graz Compositions comprising cationic and neutral lipids for transfecting nucleic acid molecules into eukaryotic cells
CN106572974B (zh) * 2014-07-15 2021-04-23 生命技术公司 用于将分子有效递送到细胞的具有脂质聚集体的组合物和方法
JP6731912B2 (ja) * 2014-09-05 2020-07-29 ノバルティス アーゲー 活性物質の送達用の脂質および脂質組成物
PL3373910T3 (pl) * 2015-11-10 2023-10-09 Children's Research Institute, Children's National Medical Center Preparat echinomycyny, sposób wytwarzania i sposób stosowania

Also Published As

Publication number Publication date
CA3113877A1 (en) 2020-05-07
CN112930172B (zh) 2023-12-22
CN112930172A (zh) 2021-06-08
EP3646854A1 (en) 2020-05-06
IL282579A (en) 2021-06-30
ES2927532T3 (es) 2022-11-08
US20210386841A1 (en) 2021-12-16
JP2022512983A (ja) 2022-02-07
WO2020089342A1 (en) 2020-05-07
AU2019373387A1 (en) 2021-04-29
PT3646854T (pt) 2022-09-27
SG11202103117RA (en) 2021-04-29
DK3646854T3 (da) 2022-09-26
KR20210084511A (ko) 2021-07-07
EP3646854B1 (en) 2022-08-03

Similar Documents

Publication Publication Date Title
IL282735A (en) Preparations and methods for t-cell engineering
IL282579A (en) Mixtures for mRNA transfection into cells and their applications
SG11202004116QA (en) T cell manufacturing compositions and methods
EP4083067A4 (en) CD7-CAR-T CELL, ITS PREPARATION AND ITS USE
IL280935A (en) Modified plant messenger packages and their uses
GB201813178D0 (en) Cell
EP3519578A4 (en) COMPOSITIONS FOR TRANSFECTION OF RESISTANT CELL TYPES
IL277673A (en) Transgenic cells and their uses
IL287874A (en) Preparations and methods for producing t cells
GB201803079D0 (en) Cell
IL290398A (en) Material transfer systems and methods
EP3813856A4 (en) CELL COMPOSITIONS AND USES THEREOF
IL282160A (en) Preparations and methods for transferring genes between cells
IL270719A (en) Biopharmaceutical compounds and related methods
GB201819540D0 (en) T cell modification
IL281531A (en) Cells produce insulin
EP3527932A4 (en) THICKNESS GAUGE FOR BATTERY MATERIAL
IL273247A (en) New cell row and its uses
EP3787688A4 (en) COMPOSITIONS FOR TRANSFECTION OF RESISTANT CELL TYPES
EP3710470A4 (en) IMMUNOREACTIVE CELLS SECRETING IL-33 AND THEIR USES
GB201807693D0 (en) Cell
GB201803363D0 (en) New materials and uses thereof
IL290109A (en) Cells for enhanced immune healing and their uses
EP3795673A4 (en) CELL FRAMEWORK MATERIAL
GB201915526D0 (en) Modified cell